MidCap Financial

MidCap is a majority-owned portfolio company of Apollo, acquired in 2011. It functions as Apollo's principal direct-origination lending platform for middle-market and healthcare borrowers. MidCap retains its own brand, origination teams, and underwriting committee, while its capital base draws heavily on Apollo's insurance subsidiaries, notably Athene.

MidCap invests from a permanent-capital base rather than from closed-end drawdown funds. Most of its capital comes from Apollo's insurance-company balance sheets and long-dated separately managed accounts. This lets MidCap hold loans to maturity without the forced-refinancing pressure that closed-end private-credit funds face.

MidCap writes senior secured loans typically between $10 million and $750 million per transaction. The sweet spot for its core middle-market direct-lending team is roughly $25 million to $200 million in hold size. Larger facilities are syndicated to club partners or other Apollo-managed vehicles.

Yes. While the majority of MidCap's middle-market direct-lending volume involves sponsor-backed companies, the firm also writes directly to family-owned and independent businesses, particularly in healthcare and life sciences. Its life-sciences practice, in particular, lends directly to venture-backed biotech and medical-device companies without sponsor intermediaries.

The primary distinction is funding architecture. Most middle-market direct lenders raise closed-end blind-pool funds with finite lives and must return capital to limited partners within a decade. MidCap sources its capital from Apollo's permanent insurance balance sheet, principally through Athene. This allows MidCap to price and structure loans with hold-to-maturity underwriting rather than exit-driven underwriting, often resulting in tighter covenant packages.